Please sign in to follow a disease.
Yoltech Therapeutics Co., Ltd
Clinical trials sponsored by Yoltech Therapeutics Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare kidney disease: experimental drug YOLT-203 enters phase 2 trial Results expected Aug 2027 (estimated)
-
Can a single gene edit stop kidney stones at the source?
Cure Recruiting nowThis early-stage trial is testing an experimental gene editing therapy called YOLT-203 in people with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes the liver to produce too much oxalate, leading to recurrent kidney stones and potential kidney failure. T…
Phase 1 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
New hope for rare kidney disease: experimental drug YOLT-203 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug, YOLT-203, in 36 children and adults with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes painful kidney stones and kidney damage. The goal is to see if a single dose can safely lower oxalate levels in urine and blood…
Phase 2 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC